Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies
Based on the hypothesis that neovascularization was required for tumor growth, the search for angiogenesis inhibitors attracted considerable attention, leading to the development of the monoclonal antibody bevacizumab against vascular endothelial growt…